NRG-GY002
|
NRG
|
A Phase II Evaluation of Nivolumab; a Fully Human Antibody against PD-1; in the Treatment of Persistent or Recurrent Cervical Cancer
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
NRG-GY003
|
NRG
|
Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
NRG-GY004
|
NRG
|
Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian; Fallopian Tube; or Primary Peritoneal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY005
|
NRG
|
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY006
|
NRG
|
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2; Stage II; IIIB; or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY007
|
NRG
|
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian; Fallopian Tube; or Primary Peritoneal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY008
|
NRG
|
A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
NRG-GY009
|
NRG
|
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY011
|
NRG
|
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
NRG-GY012
|
NRG
|
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|